Is PMS relief becoming a consumer wellness category? Bayer’s Midol in Motion campaign suggests so
PMS relief is moving beyond pain pills. Bayer’s Midol campaign ties symptom care to movement, creators, and menstrual wellness.
Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?
Viatris has patch expertise. FDA scrutiny now decides whether lower estrogen and adhesion data can turn MR-100A-01 into a real growth lever.
Is Noema Pharma AG building a multi-symptom menopause therapy platform with cendifensine?
Is Noema Pharma AG building a menopause therapy platform? Discover how cendifensine could reshape non-hormonal treatment strategies
Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma
Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.
Can Vistagen turn refisolone into a fast-acting alternative for menopausal hot flashes?
Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.
Can Uqora’s Target expansion turn urinary health into a mainstream wellness category?
Uqora has entered Target stores and Target.com. Find out what this expansion means for urinary health retail and women’s wellness growth.
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic
Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Can Peri turn perimenopause tracking into a credible new women’s health device category?
Peri has launched a perimenopause wearable, but can symptom tracking become clinical-grade insight? Read the deeper industry analysis now.
Organon & Co. strengthens LARC strategy with MIUDELLA license from Sebela Pharmaceuticals
Organon & Co. licenses MIUDELLA copper IUD. Explore what this means for hormone-free contraception and LARC competition. Read the analysis.